Dieting déjà vu…? Say no to yo-yo dieting and make this your last New Year resolution to lose weight
New research has revealed that almost 20 million adults are looking to lose weight, and of these, almost two-thirds are likely to make it their New Year resolution.
Visceral Fat & the Weight Debate: why we must act now
A new report issued today reveals that an alarming 88% of Europeans surveyed are unaware of
a significant health risk that could shorten their lives.
New research shows taking alli in conjunction with a diet significantly reduces dangerous visceral fat
Findings presented today at the 1st International Congress on Abdominal Obesity in Hong Kong
Frequently asked questions about alli®
What your audience really wants to know
Positive opinion press release
GlaxoSmithKline receives positive opinion for alli (orlistat 60 mg) as a non-prescription weight loss aid in Europe.
Licence consumer press release
GlaxoSmithKline receives authorisation to market alli (orlistat 60 mg) - alli to be available soon from UK pharmacies.
Launch consumer press release
alli launches in the UK The new clinically proven weight loss aid available from pharmacies tomorrow.
alli (pronounced AL-eye) is a weight loss aid designed to be used with the alli programme, to support the individual on their weight loss journey and guide them towards their goals.
alli (pronounced AL-eye) is the first and only non–prescription weight loss aid to receive an EU licence from the European Commission.
Putting Obesity in context
The extent of being overweight is determined in various ways. The most common method of determining weight status is Body Mass Index or BMI. It is defined as the weight in kilogrammes divided by the square of the height in metres (kg/m2).
What is the alli diet plan book?
healthcare professional press releases